Notification:
Guru Gobind Singh Indraprastha University (GGSIPU) has introduced a new Master of Pharmacy (MPharma) program starting from the 2024–25 academic session. The university will offer this program at the Centre of Excellence in Pharmaceutical Sciences (CEPS) at the Dwarka campus, where 60 seats will be available for aspiring students.
The admission process for the MPharma program is now open. Interested candidates can apply using the offline form available on the university’s website. They should submit the completed form, along with a demand draft of Rs 2,500 in favor of the registrar, to the University Facilitation Centre by August 14, 2024, before 3 p.m. Candidates should check detailed information on the university’s official websites: ipu.ac.in and ipu.admissions.nic.in.
Candidates must hold aBPharma degree with a minimum of 55 percent marks to qualify for the MPharma program. The university will primarily base admissions on the merit of marks obtained in the national-level test, GPAT. If GPAT applicants are insufficient, the university will consider the marks obtained in the qualifying exam.
The two-year MPharma program aims to equip students with in-depth knowledge and skills in pharmaceutical sciences. The curriculum will cover the latest advancements and trends in the pharmaceutical industry, preparing graduates for diverse professional roles within the sector. Students will engage in hands-on training, research projects, and industry internships, providing a comprehensive educational experience.
GGSIPU's launch of the MPharma program demonstrates its commitment to expanding educational opportunities and enhancing academic offerings. The Centre of Excellence in Pharmaceutical Sciences (CEPS) at the Dwarka campus will feature state-of-the-art facilities and a dedicated faculty focused on delivering high-quality education and fostering innovation in pharmaceutical sciences.
Prospective students should apply early to take advantage of this opportunity to advance their careers in the pharmaceutical industry through GGSIPU new MPharma program.